Payment overview · 2025
General Payments
$360.98
16 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher Coppola, DO
Allopathic & Osteopathic Physicians|Family Medicine · VERO BEACH, FL · NPI 1003803909
Verified facts
What the public records show
CMS Open Payments records show Christopher Coppola, DO received $360.98 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.59 | 30.4% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $57.33 | 15.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.07 | 15.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.08 | 13.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.90 | 8.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.91 | 6.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.96 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.14 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.98 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.29 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $57.07 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $33.79 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 126 |
| Lisinopril | Lisinopril | 255 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 89 |
| Metformin Hcl | Metformin Hcl | 174 | 56 |
| Losartan Potassium | Losartan Potassium | 164 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 55 |
| Omeprazole | Omeprazole | 150 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 38 |
| Gabapentin | Gabapentin | 113 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 34 |
| Trazodone Hcl | Trazodone Hcl | 87 | 31 |
| Glipizide | Glipizide | 74 | 22 |
| Alendronate Sodium | Alendronate Sodium | 71 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 20 |
| Simvastatin | Simvastatin | 70 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 21 |
| Allopurinol | Allopurinol | 61 | 20 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 24 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Carvedilol | Carvedilol | 52 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Buspirone Hcl | Buspirone Hcl | 51 | 20 |
| Eliquis | Apixaban | 47 | 14 |
| Furosemide | Furosemide | 44 | 15 |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Atenolol | Atenolol | 42 | 16 |
| Temazepam | Temazepam | 42 | suppressed |
| Famotidine | Famotidine | 41 | 14 |
| Ozempic | Semaglutide | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Montelukast Sodium | Montelukast Sodium | 34 | 13 |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 14 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.98 · 16 records | Novo Nordisk Inc | Arikayce, Brinsupri, General - Pain Management, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, VIVITROL, VYNDAQEL | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error